Table 1 Characteristics of the included studies (N=306)
| Â | N | % |
|---|---|---|
2018 Journal Impact Factor | ||
 No JIF | 27 | 9% |
 0–5 | 200 | 65% |
 5–10 | 63 | 21% |
 10+ | 16 | 5% |
Open access | ||
 No | 155 | 51% |
 Yes | 151 | 49% |
Journal data sharing policy | ||
 No policy | 67 | 22% |
 Encourage | 147 | 48% |
 Share on request | 4 | 1% |
 Some mandatory | 59 | 19% |
 All mandatory | 29 | 9% |
Journal code sharing policy | ||
 No policy | 202 | 66% |
 Encourage | 88 | 29% |
 Share on request | 6 | 2% |
 Some mandatory | 3 | 1% |
 All mandatory | 7 | 2% |
Journal DAS policy | ||
 Not required | 255 | 83% |
 Required | 51 | 17% |
Location of first author | ||
 North America | 72 | 24% |
 Asia | 139 | 45% |
 Europe | 72 | 24% |
 North Africa/Middle East | 11 | 4% |
 Oceania | 5 | 2% |
 South America | 2 | 1% |
 Central America/Caribbean | 2 | 1% |
 Sub-Saharan Africa | 3 | 1% |
Research area (CSO classification)a | ||
 Biology | 69 | 23% |
 Aetiology | 20 | 7% |
 Prevention | 4 | 1% |
 Detection, diagnosis and prognosis | 92 | 30% |
 Treatment | 112 | 37% |
 Control, survivorship and outcomes | 51 | 17% |
Clinical trial | ||
 No | 291 | 95% |
 Yes (phase III) | 4 | 1% |
 Yes (other phase) | 11 | 4% |
Cancer rarity | ||
 Common | 150 | 49% |
 Rare | 118 | 39% |
 Mixed | 28 | 9% |
 Other | 10 | 3% |
Data sourced froma | ||
 Human subjects | 177 | 58% |
 Human cells | 111 | 36% |
 Animal analogues | 66 | 22% |
 Animal cells | 65 | 21% |
 Commercial cell lines | 116 | 38% |
 Simulations | 3 | 1% |
Collected data from human participants | ||
 Yes | 225 | 74% |
 No | 81 | 26% |
Used publicly available data | ||
 No | 218 | 71% |
 Yes (partially) | 57 | 19% |
 Yes (exclusively) | 31 | 10% |
Citations accumulated | ||
 Median (IQR) (year 1) | 2 | 0 to 4 |
 Median (IQR) (year 2) | 3 | 1 to 7 |